155 related articles for article (PubMed ID: 37590985)
21. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis.
Hecht JL; Ince TA; Baak JP; Baker HE; Ogden MW; Mutter GL
Mod Pathol; 2005 Mar; 18(3):324-30. PubMed ID: 15529181
[TBL] [Abstract][Full Text] [Related]
22. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
23. Risk of coexisting endometrial carcinoma in case of atypical endometrial hyperplasia diagnosed on total hysteroscopic resection.
Pivano A; Crochet P; Carcopino X; Cravello L; Boubli L; Agostini A
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():210-3. PubMed ID: 27343737
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
25. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
[TBL] [Abstract][Full Text] [Related]
26. Current management of endometrial hyperplasia and endometrial intraepithelial neoplasia (EIN).
Gültekin M; Diribaş K; Dursun P; Ayhan A
Eur J Gynaecol Oncol; 2009; 30(4):396-401. PubMed ID: 19761130
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of endometrial hyperplasia: A UK national audit of adherence to national guidance 2012-2020.
Henderson I; Black N; Khattak H; ; Gupta JK; Rimmer MP
PLoS Med; 2024 Feb; 21(2):e1004346. PubMed ID: 38421942
[TBL] [Abstract][Full Text] [Related]
28. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
29. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma.
Hubbs JL; Saig RM; Abaid LN; Bae-Jump VL; Gehrig PA
Obstet Gynecol; 2013 Jun; 121(6):1172-1180. PubMed ID: 23812449
[TBL] [Abstract][Full Text] [Related]
30. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
[TBL] [Abstract][Full Text] [Related]
31. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?
Travaglino A; Raffone A; Saccone G; Mascolo M; Pignatiello S; Mollo A; De Placido G; Insabato L; Zullo F
APMIS; 2019 Apr; 127(4):161-169. PubMed ID: 30803040
[TBL] [Abstract][Full Text] [Related]
32. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
[TBL] [Abstract][Full Text] [Related]
33. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
34. Endometrial intraepithelial neoplasia.
Owings RA; Quick CM
Arch Pathol Lab Med; 2014 Apr; 138(4):484-91. PubMed ID: 24678678
[TBL] [Abstract][Full Text] [Related]
35. Clinical Predictive Factors of Response to Treatment in Patients Undergoing Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer.
Raffone A; Travaglino A; Flacco ME; Iasevoli M; Mollo A; Guida M; Insabato L; Di Spiezio Sardo A; Carugno J; Zullo F
J Adolesc Young Adult Oncol; 2021 Apr; 10(2):193-201. PubMed ID: 32799597
[No Abstract] [Full Text] [Related]
36. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.
Raffone A; Travaglino A; Saccone G; Di Maio A; Mollo A; Mascolo M; De Rosa R; De Placido G; Insabato L; Zullo F
Gynecol Endocrinol; 2019 Nov; 35(11):932-937. PubMed ID: 31165649
[No Abstract] [Full Text] [Related]
37. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
[No Abstract] [Full Text] [Related]
38. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
[TBL] [Abstract][Full Text] [Related]
39. Endometrial intraepithelial neoplasia.
Jarboe EA; Mutter GL
Semin Diagn Pathol; 2010 Nov; 27(4):215-25. PubMed ID: 21309257
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
